A Phase 4 interventional study of E2020 and Placebo in Dementia, Lewy Body and Lewy Body Disease, sponsored by Eisai Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 50 Years to 99 Years. Per ClinicalTrials.gov, last updated 2019-01-08.
Sponsored by Eisai Co., Ltd. · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to confirm the efficacy of Aricept in patients with dementia with Lewy bodies (DLB).
239 studies on the registry are indexed under Lewy Body Disease; 88 are open to participants now.
This study's enrollment of 160 is above the median of 86 across 152 interventional studies indexed under Lewy Body Disease.
Browse Lewy Body Disease studies →Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, Weeks 7-12 E2020 10 mg. Extension period: Weeks 1-6 E2020 10 mg, After Week 7 up to week 60 E2020 10 mg.
Drug: E2020
Treatment period: Weeks 1-12 placebo Extension period: Weeks 1-2 E2020 3 mg, Weeks 3-6 E2020 5 mg, After Week 7 up to week 60 E2020 10 mg.
Drug: Placebo
E2020 tablets will be orally administered once daily after breakfast
Matching placebo tablets will be orally administered once daily after breakfast
Clinician's Interview-Based Impression of Change, Plus Caregiver Input Version (CIBIC-plus)
CIBIC plus is a clinician's interview-based impression of change plus the caregiver's input. It is a seven-point categorical assessment scale for evaluating global clinical function, ranging from "markedly improved" to "markedly worse".
Time frame: Up to 12 weeks
Ran from Mar 2015 to primary completion in May 2017, 26 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Donepezil